Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from the National Medical Products Administration (NMPA) for its anti-tumor drugs SHR-9803 and SHR-A2102. This marks a significant step forward in the development of these promising therapies.
SHR-9803: Targeting Regulatory T Cells
SHR-9803, a Category 1 biologic product, will be tested as a monotherapy in advanced solid tumors. The drug specifically binds to and clears regulatory T cells (Tregs) within tumors while minimizing its impact on peripheral Tregs. This selective action helps avoid excessive activation of peripheral immunity, thereby improving both safety and efficacy. No similar product has been approved anywhere in the world, highlighting the innovative nature of SHR-9803.
SHR-A2102: Nectin-4-Targeted ADC
SHR-A2102 is an in-house developed Nectin-4-targeted antibody drug conjugate (ADC) with a topoisomerase inhibitor (TOPi) as its payload. The drug will be assessed in a multi-center, open Phase II study in advanced solid tumors when combined with adebrelimab and bevacizumab. While comparable drugs like Pfizer/Astellas’ Padcev (enfortumab vedotin) are already on the market, SHR-A2102 represents Hengrui’s entry into this competitive space with a potentially differentiated offering.-Fineline Info & Tech
Leave a Reply